Susquehanna International Group, LLP Biocryst Pharmaceuticals Inc Put Options Transaction History

Susquehanna International Group, LLP

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	SELL	$6.41 - $8.69 $151,917 - $205,953	-23,700 Reduced 22.03%	83,900 $637,000
Q2 2024 Aug 15, 2024	SELL	$4.13 - $6.79 $1.2 Million - $1.97 Million	-290,600 Reduced 72.98%	107,600 $664,000
Q1 2024 May 07, 2024	BUY	$4.89 - $7.65 $1.31 Million - $2.06 Million	268,700 Added 207.49%	398,200 $2.02 Million
Q4 2023 Feb 14, 2024	SELL	$4.98 - $6.77 $6,474 - $8,801	-1,300 Reduced 0.99%	129,500 $775,000
Q3 2023 Nov 14, 2023	SELL	$6.71 - $7.92 $149,633 - $176,616	-22,300 Reduced 14.57%	130,800 $926,000
Q2 2023 Aug 11, 2023	SELL	$6.96 - $8.81 $312,504 - $395,569	-44,900 Reduced 22.68%	153,100 $1.08 Million
Q1 2023 May 16, 2023	SELL	$7.94 - $11.84 $1.21 Million - $1.81 Million	-152,500 Reduced 43.51%	198,000 $1.65 Million
Q4 2022 Feb 14, 2023	SELL	$10.5 - $14.2 $186,900 - $252,760	-17,800 Reduced 4.83%	350,500 $4.02 Million
Q3 2022 Nov 14, 2022	SELL	$10.79 - $14.81 $2.17 Million - $2.98 Million	-201,100 Reduced 35.32%	368,300 $4.64 Million

278

172M

625K

739K

Ticker BCRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,944,992
Market Cap $1.41B
Description
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.